The DELIVER Trial
It has been reported at the 2022 European Society of Cardiology Congress that the DELIVER trial has met its primary outcome - a relative reduction of 18% in a composite of worsening heart failure (HF) or cardiovascular death. These results, added to evidence from previously reported pivotal trials w...
| Autor: | |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:273232 |
| Acceso en línea: | https://ddd.uab.cat/record/273232 https://dx.doi.org/urn:doi:10.15420/ecr.2022.44 |
| Access Level: | acceso abierto |
| Palabra clave: | Heart failure Dapagliflozin Ejection fraction Natriuretic peptides Diagnosis Sodium-glucose cotransporter-2 inhibitors |
| Sumario: | It has been reported at the 2022 European Society of Cardiology Congress that the DELIVER trial has met its primary outcome - a relative reduction of 18% in a composite of worsening heart failure (HF) or cardiovascular death. These results, added to evidence from previously reported pivotal trials with sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with reduced and preserved heart failure (HF), provide compelling evidence of the benefit of SGLT2is across the HF spectrum, irrespective of ejection fraction. New diagnostic algorithms that are quick and easy to implement at the point of care are needed for quick diagnosis and implementation of these drugs. Ejection fraction may come later for proper phenotyping. |
|---|